Dr. Karnes' primary area of research interest is cardiovascular pharmacogenomics, specifically investigating the utility of genetic polymorphisms to predict toxicities of cardiovascular drugs. He uses a translational approach to investigate pharmacogenomic associations using observational studies, functional genomics techniques, and eventually prospective clinical trials. His ultimate career goal is to facilitate personalized cardiovascular medicine and genotype-guided prescribing to avoid serious cardiovascular drug toxicities.
